IN2014MN01781A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MN01781A IN2014MN01781A IN1781MUN2014A IN2014MN01781A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A IN 1781MUN2014 A IN1781MUN2014 A IN 1781MUN2014A IN 2014MN01781 A IN2014MN01781 A IN 2014MN01781A
- Authority
- IN
- India
- Prior art keywords
- cdim
- binding proteins
- cells
- well
- diagnostic assays
- Prior art date
Links
- 102000014914 Carrier Proteins Human genes 0.000 abstract 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 4
- 108091008324 binding proteins Proteins 0.000 abstract 4
- 238000003556 assay Methods 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000025171 antigen binding proteins Human genes 0.000 abstract 1
- 108091000831 antigen binding proteins Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000030833 cell death Effects 0.000 abstract 1
- 230000000779 depleting effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Neurosurgery (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present disclosure relates to Cell Death Inducing Molecule ('CDIM') binding proteins and pharmaceutical compositions thereof. Particularly the disclosure provides CDIM binding proteins that are useful in the selective depleting and killing of B cells including neoplastic B cells as well as neoplastic cells that are not of B cell origin that express CDIM like antigens. In addition the disclosure encompasses polynucleotides encoding the disclosed antigen binding proteins and expression systems for producing the same. Further the present disclosure encompasses methods of treating patients with B cell proliferative and mediated diseases by administering the CDIM binding proteins as well as diagnostic assays for identifying proteins that bind to CDIM. The disclosure further contemplates diagnostic assays for identifying patient populations that can be treated with the CDIM binding proteins.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261633330P | 2012-02-08 | 2012-02-08 | |
| PCT/US2013/025430 WO2013120012A2 (en) | 2012-02-08 | 2013-02-08 | Cdim binding proteins and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN01781A true IN2014MN01781A (en) | 2015-07-03 |
Family
ID=48045015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1781MUN2014 IN2014MN01781A (en) | 2012-02-08 | 2013-02-08 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9409976B2 (en) |
| EP (1) | EP2812356B1 (en) |
| JP (1) | JP6335796B2 (en) |
| KR (1) | KR102102111B1 (en) |
| CN (1) | CN104254544B (en) |
| AU (1) | AU2013200903B2 (en) |
| BR (1) | BR112014019459B1 (en) |
| CA (1) | CA2863714C (en) |
| DK (1) | DK2812356T3 (en) |
| ES (1) | ES2735289T3 (en) |
| IN (1) | IN2014MN01781A (en) |
| MX (1) | MX363819B (en) |
| TW (1) | TWI606064B (en) |
| WO (1) | WO2013120012A2 (en) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014332458B2 (en) | 2013-09-05 | 2020-03-12 | Igm Biosciences, Inc. | Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies |
| ES2729057T3 (en) | 2013-12-17 | 2019-10-30 | Aimm Therapeutics Bv | Means and methods to counteract myeloproliferative or lymphoproliferative disorders |
| CN105992772A (en) | 2014-02-10 | 2016-10-05 | Igm生命科学股份有限公司 | IgA multispecific binding molecule |
| RU2761118C2 (en) | 2014-04-03 | 2021-12-06 | АйДжиЭм БАЙОСАЙЕНСИЗ, ИНК. | Modified j-strain |
| IL308212A (en) | 2015-01-20 | 2024-01-01 | Igm Biosciences Inc | Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof |
| SG10202109717TA (en) * | 2015-03-04 | 2021-10-28 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| KR102558839B1 (en) | 2015-03-25 | 2023-07-25 | 아이쥐엠 바이오사이언스 인코포레이티드 | Multivalent hepatitis B virus antigen-binding molecules and uses thereof |
| CA2983034A1 (en) | 2015-04-17 | 2016-10-20 | Igm Biosciences, Inc. | Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof |
| DK3355913T3 (en) | 2015-09-30 | 2024-12-02 | Igm Biosciences Inc | BINDING MOLECULES WITH MODIFIED J-CHAIN |
| ES2819870T3 (en) | 2015-09-30 | 2021-04-19 | Igm Biosciences Inc | Modified J-chain binding molecules |
| IL262295B2 (en) | 2016-05-09 | 2023-09-01 | Igm Biosciences Inc | Anti-pd-l1 antibodies |
| PL3733712T3 (en) * | 2016-08-15 | 2023-10-16 | Novartis Ag | TREATMENT SCHEDULES AND METHODS OF TREATING MULTIPLE SCLEROSIS USING OFATUMUMAB |
| IL268554B2 (en) | 2017-02-08 | 2025-03-01 | Dragonfly Therapeutics Inc | Multispecific binding proteins for activation of NATURAL KILLER CELLS and their medical uses for cancer treatment |
| EP3579866A4 (en) * | 2017-02-08 | 2020-12-09 | Dragonfly Therapeutics, Inc. | HEAVY CHAIN VARIABLE ANTIBODY DOMAINS WITH NKG2D RECEPTOR AIMING |
| FI3582806T3 (en) | 2017-02-20 | 2023-09-07 | Dragonfly Therapeutics Inc | HER2, NKG2D AND CD16 BINDING PROTEINS |
| CN110536900B (en) | 2017-04-07 | 2024-06-11 | Igm生物科学股份有限公司 | Modified human IGM constant regions that modulate complement-dependent cytolytic effector functions |
| US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
| KR20200118824A (en) | 2018-02-08 | 2020-10-16 | 드래곤플라이 쎄라퓨틱스, 인크. | Combination therapy for cancer involving multi-specific binding proteins that activate natural killer cells |
| JP7353576B2 (en) | 2018-02-20 | 2023-10-02 | ドラゴンフライ セラピューティクス， インコーポレイテッド | Multispecific binding proteins that bind to CD33, NKG2D, and CD16, and methods of use thereof |
| JP7376490B2 (en) | 2018-03-01 | 2023-11-08 | アイジーエム バイオサイエンシズ インコーポレイテッド | IgM Fc and J chain mutations affecting IgM serum half-life |
| EA202091888A1 (en) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | VARIABLE ANTIBODY DOMAINS TARGETED ON THE NKG2D RECEPTOR |
| WO2020033630A1 (en) | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use |
| MA53284A (en) | 2018-08-08 | 2022-01-26 | Dragonfly Therapeutics Inc | NKG2D, CD16 AND TUMOR ASSOCIATED ANTIGEN BINDING PROTEINS |
| MX2021005751A (en) * | 2018-11-16 | 2021-10-01 | Memorial Sloan Kettering Cancer Center | ANTIBODIES AGAINST MUCIN 16 AND METHODS OF USE THEREOF. |
| MX2022001934A (en) | 2019-08-15 | 2022-03-11 | Igm Biosciences Inc | Immunostimulatory multimeric binding molecules. |
| AR122018A1 (en) | 2020-05-06 | 2022-08-03 | Dragonfly Therapeutics Inc | NKG2D, CD16 AND CLEC12A BINDING PROTEINS |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| CN114181318B (en) * | 2021-11-08 | 2023-08-01 | 四川大学 | Recombinant adeno-associated virus for tissue-specific expression of IDUA fusion protein penetrating blood brain barrier and application thereof |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
| US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
| US4831175A (en) | 1986-09-05 | 1989-05-16 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5246692A (en) | 1986-09-05 | 1993-09-21 | The United States Of America As Represented By The Secretary Of Health And Human Services | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US5099069A (en) | 1986-09-05 | 1992-03-24 | Gansow Otto A | Backbone polysubstituted chelates for forming a metal chelate-protein conjugate |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| DE3920358A1 (en) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE |
| US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| US5124471A (en) | 1990-03-26 | 1992-06-23 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Bifunctional dtpa-type ligand |
| WO1993011161A1 (en) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US6312691B1 (en) | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US6962979B1 (en) | 1995-03-14 | 2005-11-08 | Cohesion Technologies, Inc. | Crosslinkable biomaterial compositions containing hydrophobic and hydrophilic crosslinking agents |
| US5855911A (en) | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
| US6680335B2 (en) | 1998-09-28 | 2004-01-20 | Sugen, Inc. | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds |
| NZ517758A (en) | 1999-09-17 | 2004-06-25 | Abbott Gmbh & Co | Pyrazolopyrimidines useful as therapeutic agents |
| US20020028178A1 (en) | 2000-07-12 | 2002-03-07 | Nabil Hanna | Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
| AU2002327164A1 (en) | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6645974B2 (en) | 2001-07-31 | 2003-11-11 | Merck & Co., Inc. | Androgen receptor modulators and methods for use thereof |
| CA2476625A1 (en) * | 2002-02-20 | 2003-08-28 | Dyax Corp. | Mhc-peptide complex binding ligands |
| US7485297B2 (en) * | 2003-08-12 | 2009-02-03 | Dyax Corp. | Method of inhibition of vascular development using an antibody |
| US20120237441A9 (en) * | 2003-11-05 | 2012-09-20 | Bhat Neelima M | Enhanced b cell cytotoxicity of cdim binding antibody |
| MXPA06005104A (en) | 2003-11-05 | 2007-01-25 | Palingen Inc | Enhanced b cell cytotoxicity of cdim binding antibody. |
| ES2551502T3 (en) * | 2004-11-05 | 2015-11-19 | Igm Biosciences, Inc. | Wound formation in the antibody-induced cell membrane |
| ATE503770T1 (en) * | 2005-03-14 | 2011-04-15 | Us Gov Health & Human Serv | HUMAN MONOCLONAL ANTIBODIES AGAINST HENDRA AND NIPAH VIRUSES |
| WO2007035857A2 (en) * | 2005-09-19 | 2007-03-29 | Palingen, Inc. | Treatment of b cell diseases using anti-germline antibody binding agents |
| TW200904470A (en) * | 2007-04-02 | 2009-02-01 | Pfizer | Anti-IgE antibodies |
-
2013
- 2013-02-08 TW TW102105337A patent/TWI606064B/en active
- 2013-02-08 AU AU2013200903A patent/AU2013200903B2/en active Active
- 2013-02-08 MX MX2014009628A patent/MX363819B/en active IP Right Grant
- 2013-02-08 JP JP2014556751A patent/JP6335796B2/en active Active
- 2013-02-08 CA CA2863714A patent/CA2863714C/en active Active
- 2013-02-08 IN IN1781MUN2014 patent/IN2014MN01781A/en unknown
- 2013-02-08 BR BR112014019459-9A patent/BR112014019459B1/en active IP Right Grant
- 2013-02-08 EP EP13713588.5A patent/EP2812356B1/en active Active
- 2013-02-08 CN CN201380008515.XA patent/CN104254544B/en active Active
- 2013-02-08 DK DK13713588.5T patent/DK2812356T3/en active
- 2013-02-08 ES ES13713588T patent/ES2735289T3/en active Active
- 2013-02-08 US US13/763,398 patent/US9409976B2/en active Active
- 2013-02-08 WO PCT/US2013/025430 patent/WO2013120012A2/en not_active Ceased
- 2013-02-08 KR KR1020147025110A patent/KR102102111B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2812356A2 (en) | 2014-12-17 |
| US9409976B2 (en) | 2016-08-09 |
| AU2013200903A1 (en) | 2013-08-22 |
| WO2013120012A2 (en) | 2013-08-15 |
| BR112014019459A2 (en) | 2017-06-27 |
| MX2014009628A (en) | 2015-03-19 |
| ES2735289T3 (en) | 2019-12-17 |
| CN104254544A (en) | 2014-12-31 |
| CN104254544B (en) | 2017-04-26 |
| DK2812356T3 (en) | 2019-07-08 |
| KR102102111B1 (en) | 2020-04-20 |
| AU2013200903B2 (en) | 2015-05-14 |
| KR20150001728A (en) | 2015-01-06 |
| JP2015511817A (en) | 2015-04-23 |
| BR112014019459B1 (en) | 2023-04-18 |
| TWI606064B (en) | 2017-11-21 |
| MX363819B (en) | 2019-04-03 |
| WO2013120012A3 (en) | 2013-11-07 |
| EP2812356B1 (en) | 2019-03-27 |
| CA2863714C (en) | 2022-07-05 |
| JP6335796B2 (en) | 2018-06-06 |
| BR112014019459A8 (en) | 2023-01-10 |
| HK1205136A1 (en) | 2015-12-11 |
| US20140044739A1 (en) | 2014-02-13 |
| CA2863714A1 (en) | 2013-08-15 |
| TW201345921A (en) | 2013-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN01781A (en) | ||
| PH12019500440A1 (en) | Monoclonal antibodies against tissue factor pathway inhibitor (tfpi) | |
| MX349096B (en) | Anti-pd-l1 antibodies and uses thereof. | |
| PH12018500639A1 (en) | Optimized monoclonal antibodies agaist tissue factor pathway inhibitor (tfpi) | |
| UA118332C2 (en) | Cs27l antigen binding proteins | |
| PH12015501092A1 (en) | Anti-ceacam5 antibodies and uses thereof | |
| PH12017501583B1 (en) | Novel proteins specific for cd137 | |
| BR112013019975A2 (en) | "Antigen binding proteins, pharmaceutical composition, use of an antigen binding protein, method for treating a patient and method for preparing an antigen binding protein, nucleic acid, vector and host cell" | |
| BR112014029099A2 (en) | anti-egfr antibodies and their use to inhibit or attenuate tumor growth, as well as a pharmaceutical composition comprising | |
| IN2014CN03936A (en) | ||
| UA107706C2 (en) | APOPTOSIS-INDUCTIVE MEANS FOR TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES | |
| PH12015500084A1 (en) | Rspo3 binding agents and uses thereof | |
| EP4509189A3 (en) | Anti-fcrn antibodies | |
| MY156286A (en) | Human il-23 antigen binding proteins | |
| JOP20210044A1 (en) | Anti-CD38 . antibody | |
| GB201201314D0 (en) | Composition | |
| PH12012500524A1 (en) | Dll4-binding molecules | |
| PH12020550598A1 (en) | Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells | |
| NZ701370A (en) | Il-6 binding molecules | |
| WO2014100857A8 (en) | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy | |
| EA201370155A1 (en) | COMPOSITION AND METHOD OF TREATMENT OF CANCER | |
| BR112012014345A2 (en) | tmem22 peptides and vaccines including the same | |
| WO2013040547A3 (en) | Compounds and methods of immunization with tumor antigens | |
| TN2013000265A1 (en) | Anti-cd38 antibodies |